Recent Quotes (30 days)

You have no recent quotes
chg | %

Ceapro Inc.  

(Public, CVE:CZO)   Watch this stock  
Find more results for CZO
+0.04 (2.82%)
Mar 29 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.42 - 1.50
52 week 0.47 - 2.47
Open 1.45
Vol / Avg. 0.00/160,406.00
Mkt cap 114.65M
P/E 12.88
Div/yield     -
EPS 0.11
Shares 75.21M
Beta 1.11
Inst. own     -

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin 21.38% 46.14%
Operating margin 30.06% 30.68%
EBITD margin - 38.20%
Return on average assets 11.88% 42.09%
Return on average equity 16.21% 98.75%
Employees 12 -
CDP Score - -


7824 51 Avenue
+1-780-4214555 (Phone)
+1-780-4214555 (Fax)

Website links


Ceapro Inc. is a Canada-based growth-stage biotechnology company. The Company's primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human and animal health industries using technology, natural and renewable resources. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides and lupin peptides, which are marketed to the personal care, cosmetic, medical and animal health industries, and Veterinary therapeutic products, including an oat shampoo, an ear cleanser and a dermal complex/conditioner, which are manufactured and marketed to veterinarians in Japan and Asia. Its other products and technologies are in the research and development or pre-commercial stage, which include a potential platform using its beta glucan formulations, and CeaProve, a diabetes test meal to screen pre-diabetes.

Officers and directors

Gilles R. Gagnon Chief Executive Officer, Director
Age: 61
Stacy Prefontaine Chief Financial Officer, Corporate Secretary
Glenn R. Rourke Independent Chairman of the Board
Ulrich Kosciessa Director
William W. Li M.D. Director
Age: 50
Donald J. Oborowsky Independent Director
John Zupancic Independent Director